PMID- 26485054 OWN - NLM STAT- MEDLINE DCOM- 20160601 LR - 20240324 IS - 1545-5017 (Electronic) IS - 1545-5009 (Print) IS - 1545-5009 (Linking) VI - 63 IP - 2 DP - 2016 Feb TI - Outcome of Children with Standard-Risk T-Lineage Acute Lymphoblastic Leukemia--Comparison among Different Treatment Strategies. PG - 255-61 LID - 10.1002/pbc.25793 [doi] AB - BACKGROUND: Children with T-lineage acute lymphoblastic leukemia ALL (T-ALL) historically have had inferior outcomes compared with the children with precursor-B ALL (B-ALL). After 1995, the Children's Cancer Group (CCG) treated patients with B- and T-ALL according to the National Cancer Institute (NCI) risk criteria, basing risk stratification on age and white blood cell (WBC) count regardless of immunophenotype. The Pediatric Oncology Group (POG) treated all the patients with T-ALL on separate, generally more intensive protocols than those used to treat the patients with B-ALL. PROCEDURE: We compared the outcomes of children with T-ALL and NCI standard-risk (SR) criteria treated on CCG and POG trials between 1996 and 2005. CCG SR-ALL 1952 and 1991 enrolled 80 and 86 patients with T-ALL, respectively, utilizing a reduced intensity Berlin-Frankfurt-Munster backbone. Treatment was intensified for slow early responders and only patients with overt central nervous system leukemia received cranial irradiation. Eighty-four patients with T-ALL and SR features were enrolled on POG 9404 comprising more intensive therapy with all patients receiving cranial irradiation. RESULTS: The 7-year event-free survival (EFS) for patients with SR T-ALL on CCG 1952, CCG 1991, and POG 9404 were 74.1 +/- 5.8%, 81.8 +/- 5.3%, and 84.2 +/- 4.3%, respectively (P = 0.18). Overall 7-year survivals were 86.1 +/- 4.6%, 88.3 +/- 4.4%, 89.1 +/- 3.6%, respectively (P = 0.84). CONCLUSIONS: Comparable high rates of EFS and long-term survival were achieved with all three regimens, with the CCG regimens utilizing a less intensive chemotherapy backbone without prophylactic cranial irradiation for patients with SR T-ALL. CI - (c) 2015 Wiley Periodicals, Inc. FAU - Matloub, Yousif AU - Matloub Y AD - Rainbow Babies & Children's Hospital, Division of Hematology-Oncology, Case Western Reserve University, Cleveland, Ohio. FAU - Stork, Linda AU - Stork L AD - Doernbecher Children's Hospital, Division of Hematology-Oncology, Oregon Health & Science University, Portland, Oregon. FAU - Asselin, Barbara AU - Asselin B AD - Department of Pediatrics, Golisano Children's Hospital, University of Rochester Medical Center, Rochester, New York. FAU - Hunger, Stephen P AU - Hunger SP AD - Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. FAU - Borowitz, Michael AU - Borowitz M AD - Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland. FAU - Jones, Tamekia AU - Jones T AD - Children's Foundation Research Institute, University of Tennessee Health Science Center, Memphis, Tennessee. FAU - Bostrom, Bruce AU - Bostrom B AD - Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota. FAU - Gastier-Foster, Julie M AU - Gastier-Foster JM AD - Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio. AD - Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio. AD - Department of Pediatrics, The Ohio State University College of Medicine, Columbus, Ohio. FAU - Heerema, Nyla A AU - Heerema NA AD - Department of Pathology, The Ohio State University College of Medicine, Columbus, Ohio. FAU - Carroll, Andrew AU - Carroll A AD - Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama. FAU - Winick, Naomi AU - Winick N AD - Division of Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, Texas. FAU - Carroll, William L AU - Carroll WL AD - New York University Cancer Institute, New York, New York. FAU - Camitta, Bruce AU - Camitta B AD - Midwest Center for Cancer and Blood Disorders, Pediatric Hematology-Oncology, Milwaukee, Wisconsin. FAU - Devidas, Meenakshi AU - Devidas M AD - Department of Biostatistics, Colleges of Medicine, Public Health & Health Professions, Children's University of Florida, Gainsville, Florida. FAU - Gaynon, Paul S AU - Gaynon PS AD - Division of Hematology-Oncology, Children's Hospital Los Angeles, University of Southern California, Los Angeles, California. LA - eng GR - U24 CA196173/CA/NCI NIH HHS/United States GR - U10CA180899/CA/NCI NIH HHS/United States GR - U10 CA098413/CA/NCI NIH HHS/United States GR - U24 CA114766/CA/NCI NIH HHS/United States GR - U10CA180886/CA/NCI NIH HHS/United States GR - U10 CA098543/CA/NCI NIH HHS/United States GR - U10 CA180899/CA/NCI NIH HHS/United States GR - U10 CA180886/CA/NCI NIH HHS/United States GR - U10 CA98543/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, N.I.H., Extramural DEP - 20151020 PL - United States TA - Pediatr Blood Cancer JT - Pediatric blood & cancer JID - 101186624 SB - IM MH - Chemoradiotherapy MH - Child MH - Child, Preschool MH - Disease-Free Survival MH - Female MH - Humans MH - Infant MH - Male MH - Precursor T-Cell Lymphoblastic Leukemia-Lymphoma/*mortality/therapy MH - Treatment Outcome PMC - PMC4715507 MID - NIHMS725424 OTO - NOTNLM OT - T-cell leukemia OT - childhood acute leukemia OT - childhood leukemia COIS- Conflict-of-interest disclosure The authors declare no competing financial interests. EDAT- 2015/10/21 06:00 MHDA- 2016/06/02 06:00 PMCR- 2017/02/01 CRDT- 2015/10/21 06:00 PHST- 2015/07/07 00:00 [received] PHST- 2015/08/26 00:00 [revised] PHST- 2015/09/11 00:00 [accepted] PHST- 2015/10/21 06:00 [entrez] PHST- 2015/10/21 06:00 [pubmed] PHST- 2016/06/02 06:00 [medline] PHST- 2017/02/01 00:00 [pmc-release] AID - 10.1002/pbc.25793 [doi] PST - ppublish SO - Pediatr Blood Cancer. 2016 Feb;63(2):255-61. doi: 10.1002/pbc.25793. Epub 2015 Oct 20.